ORGANOGENESIS HOLDINGS INC. Finite-Lived Intangible Asset, Expected Amortization, Year One
ORGANOGENESIS HOLDINGS INC. (ORGO) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $3.04 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2026-02-26
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $3.04M.
- 2024-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $3.32M.
- 2023-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $3.40M.
- 2022-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $4.92M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2025-12-31 | $3.04M 10-K · filed 2026-02-26 |
| 2024-12-31 | $3.32M 10-K · filed 2025-02-27 |
| 2023-12-31 | $3.40M 10-K · filed 2024-02-29 |
| 2022-12-31 | $4.92M 10-K · filed 2023-03-01 |
| 2021-12-31 | $4.88M 10-K · filed 2022-03-01 |
| 2020-12-31 | $4.95M 10-K · filed 2021-03-16 |
| 2019-12-31 | $3.27M 10-K · filed 2020-03-09 |
| 2018-12-31 | $5.99M 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |